Research And Development Expense of CureVac N.V. from 31 Dec 2018 to 31 Dec 2024

Taxonomy & unit
ifrs-full: EUR
Summary
CureVac N.V. quarterly and annual Research And Development Expense in EUR history and change rate from 31 Dec 2018 to 31 Dec 2024.
  • CureVac N.V. Research And Development Expense for the quarter ending 31 Dec 2024 was €44,137,000, a 32% increase year-over-year.
  • CureVac N.V. Research And Development Expense for the twelve months ending 31 Dec 2024 was €153,034,000, a 32% increase year-over-year.
  • CureVac N.V. annual Research And Development Expense for 2024 was €153,034,000, a 32% increase from 2023.
  • CureVac N.V. annual Research And Development Expense for 2023 was €115,724,000, a 85% increase from 2022.
  • CureVac N.V. annual Research And Development Expense for 2022 was €62,550,000, a 92% decline from 2021.
Source SEC data
View on sec.gov
Research And Development Expense, Trailing 12 Months (EUR)
Research And Development Expense, Quarterly (EUR)
Research And Development Expense, YoY Quarterly Change (%)
Research And Development Expense, Annual (EUR)
Research And Development Expense, YoY Annual Change (%)

CureVac N.V. Quarterly Research And Development Expense (EUR)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q4 2024 €153,034,000 €44,137,000 +€10,777,000 +32% 01 Oct 2024 31 Dec 2024 20-F 11 Apr 2025 2024 FY
Q3 2024 €142,257,000 €49,979,000 +€22,734,000 +83% 01 Jul 2024 30 Sep 2024 6-K 12 Nov 2024 2024 Q3
Q2 2024 €119,523,000 €31,093,000 +€225,000 +0.73% 01 Apr 2024 30 Jun 2024 6-K 15 Aug 2024 2024 Q2
Q1 2024 €119,298,000 €27,825,000 +€3,574,000 +15% 01 Jan 2024 31 Mar 2024 6-K 23 May 2024 2024 Q1
Q4 2023 €115,724,000 €33,360,000 +€5,743,000 +21% 01 Oct 2023 31 Dec 2023 20-F 11 Apr 2025 2024 FY
Q3 2023 €109,981,000 €27,245,000 +€14,733,000 +118% 01 Jul 2023 30 Sep 2023 6-K 12 Nov 2024 2024 Q3
Q2 2023 €95,248,000 €30,868,000 +€19,233,000 +165% 01 Apr 2023 30 Jun 2023 6-K 15 Aug 2024 2024 Q2
Q1 2023 €76,015,000 €24,251,000 +€13,465,000 +125% 01 Jan 2023 31 Mar 2023 6-K 23 May 2024 2024 Q1
Q4 2022 €62,550,000 €27,617,000 01 Oct 2022 31 Dec 2022 20-F 11 Apr 2025 2024 FY
Q3 2022 €12,512,000 01 Jul 2022 30 Sep 2022 6-K 14 Nov 2023 2023 Q3
Q2 2022 €11,635,000 01 Apr 2022 30 Jun 2022 6-K 17 Aug 2023 2023 Q2
Q1 2022 €10,786,000 -€94,200,000 -90% 01 Jan 2022 31 Mar 2022 6-K 30 May 2023 2023 Q1
Q1 2021 €104,986,000 01 Jan 2021 31 Mar 2021 6-K 25 May 2022 2022 Q1

CureVac N.V. Annual Research And Development Expense (EUR)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 €153,034,000 +€37,310,000 +32% 01 Jan 2024 31 Dec 2024 20-F 11 Apr 2025 2024 FY
2023 €115,724,000 +€53,174,000 +85% 01 Jan 2023 31 Dec 2023 20-F 11 Apr 2025 2024 FY
2022 €62,550,000 -€753,357,000 -92% 01 Jan 2022 31 Dec 2022 20-F 11 Apr 2025 2024 FY
2021 €815,907,000 +€702,099,000 +617% 01 Jan 2021 31 Dec 2021 20-F 25 Apr 2024 2023 FY
2020 €113,808,000 +€70,566,000 +163% 01 Jan 2020 31 Dec 2020 20-F/A 12 Oct 2023 2022 FY
2019 €43,242,000 +€1,520,000 +3.6% 01 Jan 2019 31 Dec 2019 20-F 28 Apr 2022 2020 FY
2018 €41,722,000 01 Jan 2018 31 Dec 2018 20-F 27 Apr 2021 2020 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.